Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.

Cytotoxic tests recently performed at National Cancer Institute, NCI (USA), on [Cu(HPIR)(2)(DMF)(2)], 1, (H(2)PIR=piroxicam, 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) a widely used non-steroidal anti-inflammatory drug, NSAID [see R. Cini, G. Giorgi, A. Cinquantini, C. Rossi, M. Sabat, Inorg. Chem. 29 (1990) 5197-5200, for synthesis and structural characterization, DMF=dimethylformamide] (NSC #624662) by using a panel of ca. 50 human cancer cells, showed growth inhibition factor GI(50) values as low as 20microM against several cancer lines, with an average value 54.4microM. The activity of 1 is larger against ovarian cancer cells, non-small lung cancer cells, melanoma cancer cells, and central nervous system cancer cells. The widely used anticancer drug carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)) (NSC #241240) has average GI(50) value of 102microM. The reactions of copper(II)-acetate with other NSAIDs from the oxicam family were tested and crystalline complexes were obtained and characterized. Isoxicam (H(2)ISO=4-hydroxy-2-methyl-N-(5-methylisoxazol-3-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) produced [Cu(HISO)(2)].0.5DMF, 2.0.5DMF (DMF=dimethylfomamide). The coordination arrangement is square-planar and the HISO(-) anions behave as ambi-dentate chelators via O(amide),N(isoxazole) and O(enolate),O(amide) donors. Meloxicam (H(2)MEL=4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) produced [Cu(HMEL)(2)(DMF)].0.25H(2)O, 3.0.25H(2)O. The coordination arrangement is square-pyramidal, the equatorial donors being O(amide),N(thiazole) from two HMEL(-) anions and the apical donor being O(DMF). Unexpectedly, cinnoxicam (HCIN=2-methyl-1,1-dioxido-3-[(pyridin-2-ylamino)carbonyl]-2H-1,2-benzothiazin-4-yl-(3-phenylacrylate)) produced [Cu(MBT)(2)(PPA)(2)] (MBT=3-(methoxycarbonyl)-2-methyl-2H-1,2-benzothiazin-4-olate 1,1-dioxide, PPA=3-phenyl-N-pyridin-2-ylacrylamide).

[1]  A. Orlandini,et al.  Speciation study of the anti-inflammatory drug tenoxicam (Htenox) with Cu(II): X-ray crystal structure of [Cu(tenox)(2)(py)(2)].EtOH. , 2003, Journal of inorganic biochemistry.

[2]  A. M. Glazer,et al.  A nitrogen‐gas‐stream cryostat for general X‐ray diffraction studies , 1986 .

[3]  E. Deydier,et al.  N-(2-pyridyl)-3-phenyl-2-propene amide (O-N) complexes fo copper(II), nickel(II), cobalt(II) and palladium(II). Crystal and molecular structure of Cu(O-N)2(CF3SO3)2 , 1993 .

[4]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[5]  P. A. Lay,et al.  Preparation and characterization of dinuclear copper–indomethacin anti-inflammatory drugs , 2001 .

[6]  R. Cini.  Synthesis, crystal structure and molecular orbital investigation of the first platinum complex of piroxicam , 1996 .

[7]  M. Jugé,et al.  Non-acidic anti-inflammatory compounds: activity of N-(4,6-dimethyl-2-pyridinyl) benzamides and derivatives , 1990 .

[8]  S. Pinelli,et al.  Copper(II) and cobalt(III) pyridoxal thiosemicarbazone complexes with nitroprusside as counterion: syntheses, electronic properties, and antileukemic activity. , 2005, Journal of medicinal chemistry.

[9]  M. Sarkar,et al.  Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone. , 2006, Journal of inorganic biochemistry.

[10]  B. Keppler,et al.  Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action. , 2005, Inorganic chemistry.

[11]  P. A. Lay,et al.  Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized , 2002 .

[12]  A. Bondi.  van der Waals Volumes and Radii , 1964 .

[13]  D. Kovala-Demertzi,et al.  Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: Organotin complexes of NSAIDs , 2006 .

[14]  S. Pinelli,et al.  Copper(II) complexes with substituted thiosemicarbazones of alpha-ketoglutaric acid: synthesis, X-ray structures, DNA binding studies, and nuclease and biological activity. , 2004, Inorganic chemistry.

[15]  J. G. Haasnoot,et al.  Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). , 2004, Journal of Medicinal Chemistry.

[16]  C. Rossi,et al.  Metal complexes of the antiinflammatory drug piroxicam , 1990 .

[17]  B. Szymańska,et al.  EPR spectroscopic study of a dinuclear copper(II) complex of tolfenamic acid , 2005 .

[18]  M. Sassi,et al.  Synthesis, characterization and X-ray structures of new antiproliferative and proapoptotic natural aldehyde thiosemicarbazones and their nickel(II) and copper(II) complexes. , 2002, Journal of inorganic biochemistry.

[19]  R. Cini,et al.  Synthesis of platinum(II)–piroxicam compounds. Crystal structure of trans-dichloro(η2-ethene)(piroxicam)platinum(II)‡ , 1998 .

[20]  P. A. Lay,et al.  Gastrointestinal toxicity, antiinflammatory activity, and superoxide dismutase activity of copper and zinc complexes of the antiinflammatory drug indomethacin. , 2003, Chemical research in toxicology.

[21]  P. A. Lay,et al.  Anti-Inflammatory Dinuclear Copper(II) Complexes with Indomethacin. Synthesis, Magnetism and EPR Spectroscopy. Crystal Structure of the N,N-Dimethylformamide Adduct. , 1999, Inorganic chemistry.

[22]  R. Basosi,et al.  Oxygen Radical Scavenger Activity, EPR, NMR, Molecular Mechanics and Extended-Hückel Molecular Orbital Investigation of the Bis(Piroxicam)Copper(II) Complex , 1995, Metal-based drugs.

[23]  D. Cremer,et al.  General definition of ring puckering coordinates , 1975 .

[24]  R. Cini.  Anti-Inflammatory Compounds as Ligands in Metal Complexes as Revealed in X-Ray Structural Studies , 2000 .

[25]  P. Emery,et al.  Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. , 2002, Clinical therapeutics.

[26]  E. Deydier,et al.  Interaction of Zn2+ with N-(2-pyridyl)-3-phenyl-2-propene amide, a model in lignin biosynthesis inhibition by cinnamides. Crystal and molecular structure of [Zn(ON)2(CH3OH)2](CF3SO3)2 , 1991 .

[27]  P. A. Lay,et al.  Nuclear magnetic resonance analysis of indomethacin-induced gastric ulcers. , 2005, Chemical research in toxicology.

[28]  R. Cini,et al.  Synthesis, X-ray structure and molecular modelling analysis of cobalt(II), nickel(II), zinc(II) and cadmium(II) complexes of the widely used anti-inflammatory drug meloxicam , 2002 .

[29]  P. Gartside,et al.  Total body burdens and tissue concentrations of lead, cadmium, copper, zinc, and ash in 55 human cadavers. , 1990, Environmental research.

[30]  P. A. Lay,et al.  Determination of the structures of antiinflammatory copper(II) dimers of indomethacin by multiple-scattering analyses of X-ray absorption fine structure data. , 2001, Inorganic chemistry.

[31]  John R. Miller,et al.  Synthesis and characterisation of the first organotin complex of piroxicam. An extended network system via non-hydrogen, hydrogen bonding linkages and C–H· · ·π contacts , 1999 .

[32]  R. Cini,et al.  Synthesis, X-ray structural characterization and solution studies of metal complexes containing the anti-inflammatory drugs meloxicam and tenoxicam , 2003 .

[33]  Saadallah Ramadan,et al.  NMR spectroscopic characterization of copper(II) and zinc(II) complexes of indomethacin. , 2004, Inorganic chemistry.

[34]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[35]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.